[
  {
    "ts": "2025-05-27T10:59:00+00:00",
    "headline": "Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada",
    "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia1. It is estimated that 25% to 30% of individuals with s",
    "url": "https://finance.yahoo.com/news/viatris-announces-launch-first-clozapine-105900469.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "d62636b9-1247-3028-bec5-463f089a2bec",
      "content": {
        "id": "d62636b9-1247-3028-bec5-463f089a2bec",
        "contentType": "STORY",
        "title": "Viatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada",
        "description": "",
        "summary": "Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the launch in Canada of Gen-Clozapine orally disintegrating tablets (ODT) (12.5 mg, 25 mg, 50 mg, 100 mg and 200 mg), providing a new treatment option for treatment-resistant schizophrenia patients. This marks the first availability in Canada of an orally disintegrating tablet of clozapine, which is the only approved antipsychotic for treatment-resistant schizophrenia1. It is estimated that 25% to 30% of individuals with s",
        "pubDate": "2025-05-27T10:59:00Z",
        "displayTime": "2025-05-27T10:59:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/c03b6c5b724244b6bb2d566254fd974b",
          "originalWidth": 400,
          "originalHeight": 112,
          "caption": "Viatris OUS Logo (PRNewsfoto/Viatris Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YeCieyraZRqzDJJQq4x0GA--~B/aD0xMTI7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 400,
              "height": 112,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o..G3kJFmn9tDGiPumTHww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/c03b6c5b724244b6bb2d566254fd974b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-launch-first-clozapine-105900469.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viatris-announces-launch-first-clozapine-105900469.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTRS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]